Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

460
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

130
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
130
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

368
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
368

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triglyceride-glucose index and its derived anthropometric indices: a comparative analysis for mortality prediction in the population cohort of the URRAH study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

[2025 AHA/ACC Guidelines on hypertension: what are the main novelties?]

Giornale italiano di cardiologia (2006)·2026
Same author

Refining the impact of epicardial adipose tissue assessment.

European journal of internal medicine·2026
Same author

Possible underdiagnosis of ulcerative colitis in tertiary care can affect medication use and access to healthcare facilities.

Frontiers in immunology·2026
Same author

Should we really target a higher blood pressure in the presence of left ventricular hypertrophy?

European journal of internal medicine·2026
Same author

The Relation Between Blood Pressure and Outcomes in Diabetes: With or Without the J Curve?

Journal of the American College of Cardiology·2026
Same journal

The great mimic: how E-FAST unmasked a cardiac rupture masquerading as head trauma.

Internal and emergency medicine·2026
Same journal

Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.

Internal and emergency medicine·2026
Same journal

Sex differences in vascular endothelial function in predicting cardiovascular events in hypertensive patients: comment.

Internal and emergency medicine·2026
Same journal

Utility of the diaphragm assessment in acute decompensated heart failure: a case series and a proof-of-concept study.

Internal and emergency medicine·2026
Same journal

When Rosai-Dorfman meets autoimmunity.

Internal and emergency medicine·2026
Same journal

Hypocholesterolemia as a predictor of mortality in infective endocarditis.

Internal and emergency medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Why switch from warfarin to NOACs?

Paolo Verdecchia1, Fabio Angeli2, Adolfo Aita3

  • 1Struttura Complessa di Medicina, Ospedale di Assisi, Via Valentin Müller, 1, 06081, Assisi, Italy. verdec@tin.it.

Internal and Emergency Medicine
|March 15, 2016
PubMed
Summary
This summary is machine-generated.

Switching patients with non-valvular atrial fibrillation from warfarin to non-vitamin K antagonist oral anticoagulants (NOACs) may reduce bleeding risks. NOACs offer benefits like fewer interactions and less monitoring, despite higher costs.

Keywords:
ApixabanAtrial fibrillationDabigatranEdoxabanRivaroxabanWarfarin

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Related Experiment Videos

Last Updated: Mar 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Warfarin (vitamin-K antagonist) is a common anticoagulant for non-valvular atrial fibrillation.
  • Challenges with warfarin include monitoring, drug/food interactions, and bleeding risks.

Purpose of the Study:

  • To evaluate the benefits of switching from warfarin to non-vitamin K antagonist oral anticoagulants (NOACs).
  • To identify patient groups who may most benefit from NOACs.

Main Methods:

  • Review of existing evidence and comparative data on NOACs versus warfarin.
  • Analysis of bleeding risk, thromboembolic complications, drug interactions, and monitoring requirements.

Main Results:

  • NOACs significantly reduce intracranial bleeding risk by 52% compared to warfarin.
  • NOACs show fewer drug-drug and drug-food interactions and require less frequent monitoring.
  • Some NOACs demonstrate superiority over warfarin in preventing thromboembolic events.

Conclusions:

  • Switching to NOACs is advisable for many patients with non-valvular atrial fibrillation, especially those at high risk for bleeding.
  • NOACs offer a safer and more convenient alternative to warfarin, though cost remains a consideration.